There are 511 resources available
29P - Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial
Presenter: Maria Elena Elez Fernandez
Session: Poster Display session
Resources:
Abstract
30P - Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC)
Presenter: Benjamin Challoner
Session: Poster Display session
Resources:
Abstract
31P - Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2
Presenter: Dirk Arnold
Session: Poster Display session
Resources:
Abstract
32P - Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study
Presenter: Julien Taieb
Session: Poster Display session
Resources:
Abstract
33P - Final analysis of the Greek cohort of the AGENT phase III study arfolitixorin in metastatic colorectal cancer
Presenter: Anna Koumarianou
Session: Poster Display session
Resources:
Abstract
34P - Circulating tumor DNA (ctDNA) testing in tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the LIquid BIopsy monoclonal Antibodies (LIBImAb) study
Presenter: Anna Maria Rachiglio
Session: Poster Display session
Resources:
Abstract
35P - Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster Display session
Resources:
Abstract
36P - Exploring the potential of Artificial intelligence: Revolutionizing treatment decision-making in metastatic colorectal cancer
Presenter: Eliza Froicu
Session: Poster Display session
Resources:
Abstract
37P - Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients
Presenter: Ian Chau
Session: Poster Display session
Resources:
Abstract
38P - Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)
Presenter: Yu Sunakawa
Session: Poster Display session
Resources:
Abstract